tiprankstipranks
Trending News
More News >
Aptorum Group (APM)
:APM
Advertisement

Aptorum Group (APM) Price & Analysis

Compare
292 Followers

APM Stock Chart & Stats


Aptorum Group News

APM FAQ

What was Aptorum Group’s price range in the past 12 months?
Aptorum Group lowest stock price was $0.46 and its highest was $7.49 in the past 12 months.
    What is Aptorum Group’s market cap?
    Aptorum Group’s market cap is $13.22M.
      When is Aptorum Group’s upcoming earnings report date?
      Aptorum Group’s upcoming earnings report date is Sep 16, 2025 which is 14 days ago.
        How were Aptorum Group’s earnings last quarter?
        Currently, no data Available
        Is Aptorum Group overvalued?
        According to Wall Street analysts Aptorum Group’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Aptorum Group pay dividends?
          Aptorum Group does not currently pay dividends.
          What is Aptorum Group’s EPS estimate?
          Aptorum Group’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Aptorum Group have?
          Aptorum Group has 5,346,823 shares outstanding.
            What happened to Aptorum Group’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Aptorum Group?
            Currently, no hedge funds are holding shares in APM

            Company Description

            Aptorum Group

            Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

            Aptorum Group (APM) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Brainstorm Cell Therapeutics
            GT Biopharma
            Lyra Therapeutics
            Conduit Pharmaceuticals
            Lipella Pharmaceuticals, Inc.

            Ownership Overview

            0.05%0.26%98.61%
            Insiders
            0.26% Other Institutional Investors
            98.61% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis